Ticker

Helen Louise Collins exercised and sold 40,000 Common Stock shares over March 9–10, 2026, generating proceeds of ~$1.20 million at a weighted average price of $30.07 per share. The transaction reduced her direct Common Stock holdings by 61.54%, from 65,000 to 25,000 shares, while indirect holdings remained at zero.

Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN - Get Free Report) hit a new 52-week high during mid-day trading on Friday. The stock traded as high as $31.76 and last traded at $30.05, with a volume of 4931441 shares. The stock had previously closed at $27.25. Analyst Upgrades and Downgrades A number of analysts have

Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN - Get Free Report) have earned an average recommendation of "Moderate Buy" from the five brokerages that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average twelve-month target

/PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and

BOULDER, Colo., Feb. 25, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 10:30 a.m.